東華大學圖書館 |

Hypertension = a companion to Brenner and Rector's the kidney /

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Hypertension/ [edited by] Suzanne Oparil, Michael A. Weber.{me_controlnum}
其他題名:	a companion to Brenner and Rector's the kidney /
其他題名:	Hypertension :
其他作者:	Oparil, Suzanne.
出版者:	Philadelphia :Elsevier Mosby, : c2005.,
面頁冊數:	xxv, 872 p. :ill. ;29 cm.
附註:	Companion v. to Brenner & Rector's the kidney / edited by Barry M. Brenner. 7th ed. c2004.
內容註:	Sect. 1. Background and history. A history of hypertension treatment -- The National High Blood Pressure Education Program -- Epidemiology of hypertension -- sect. 2. Pathophysiology. Pathophysiology of hypertension -- Blood pressure genetics -- The sympathetic nervous system in acute and chronic blood pressure elevation -- Environmental and psychosocial stress in hypertension onset and progression -- Renin -- Angiotensin-converting enzymes: properties and function -- Angiotensin-(1-7) -- The angiotensin receptors: AT b1 s and AT b2 s -- Aldosterone and mineralocorticoids -- The role of insulin resistance and compensatory hyperinsulinemia in patients with essential hypertension -- Remodeling of resistance arteries in hypertension -- Clinical applications of arterial stiffness in hypertension -- Endothelium in hypertension: nitric oxide --Endothelin in hypertension -- Natriuretic peptides -- Vasodilator peptides: CGRP, substance P, and adrenomedullin -- The Kallikrein-Kinin System as a regulator of cardiovascular and renal function -- Sect. 3. Target organ damage/cardiovascular events. The concept of total risk -- New interpretations of blood pressure: the importance of pulse pressure -- Coronary atherosclerotic sequelae of hypertension -- Left ventricular hypertrophy, congestive heart failure, and coronary flow reserve abnormalities in hypertension -- Renal protection in chronic kidney disease -- sect. 4. Diagnosis. Initial evaluation and follow-up assessment -- Prognostic and diagnostic value of ambulatory blood pressure monitoring -- White-coat hypertension -- Sect. 5. Treatment: general considerations. The blood pressure lowering treatment trialists' collaboration (BPLTTC) -- The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT) -- The LIFE study -- The VALUE trial -- Main results from VALUE -- Clinical outcome trials of hypertension with angiotensin receptor blockers -- ACE inhibitor trials: effects in hypertension -- Critical assessment of hypertension guidelines -- Current prescribing practices -- Calcium channel blockers: controversies, lessons, and outcomes -- Nursing clinics in the management of hypertension -- Community outreach -- Medication adherence for antihypertensive therapy -- Sect. 6. Diet and nutrition. Diet: micronutrients -- Dietary approaches to hypertension management: the DASH studies -- Obesity and hypertension: impact on the cardiovascular and renal systems -- Alcohol and hypertension -- Obesity in hypertension: the role of diet and drugs -- Exercise and hypertension -- Sect. 7. Pharmacologic treatment. Initial choices in the treatment of hypertension -- Pharmacokinetics of antihypertensive drugs -- Fixed combination antihypertensive therapy -- Chronotherapeutics in the treatment of hypertension -- Sect. 8. Comorbid conditions and special populations in hypertension. Diabetes mellitus and the cardiovascular metabolic syndrome: reducing cardiovascular and renal events -- Hypertension in patients on renal replacement therapy -- Ischemic heart disease in hypertension -- Hypertension in the elderly -- Management of hypertension in Black populations -- Hypertension in pregnancy -- Hypertension in children -- Resistant hypertension -- Orthostatic hypotension and autonomic dysfunction syndromes -- Sect. 9. Individual drug classes. How antihypertensive drugs get approved in the United States -- Diuretics: mechanisms of action -- [beta]-adrenergic blockers -- [alpha]-adrenoceptor blockers -- Angiotensin-converting enzyme inhibitors -- Calcium antagonists -- Angiotensin II receptor antagonists -- Direct-acting smooth muscle vasodilators and adrenergic inhibitors -- Endothelin antagonists -- Mineralocorticoid receptor antagonists -- Vasopeptidase inhibitors -- Renin inhibitors -- Sect. 10. Secondary hypertension. Obstructive sleep apnea and hypertension -- Renovascular hypertension: diagnosis and treatment -- Adrenal cortex hypertension -- Phoechromocytoa: detection and management -- Anesthesia and hypertension -- Management of hypertensive emergencies and urgencies -- Aggressive blood pressure targets; developing effective algorithms.
標題:	Hypertension. -
電子資源:	http://www.sciencedirect.com/science/book/9780721602585An electronic book accessible through the World Wide Web; click for information
ISBN:	9780721602585

Hypertension = a companion to Brenner and Rector's the kidney /
Hypertensiona companion to Brenner and Rector's the kidney /[electronic resource] :Hypertension :a companion to Brenner and Rector's the kidney (Online)[edited by] Suzanne Oparil, Michael A. Weber.{me_controlnum} - 2nd ed. - Philadelphia :Elsevier Mosby,c2005. - xxv, 872 p. :ill. ;29 cm.

Companion v. to Brenner & Rector's the kidney / edited by Barry M. Brenner. 7th ed. c2004.

Includes bibliographical references and index.

Sect. 1. Background and history. A history of hypertension treatment -- The National High Blood Pressure Education Program -- Epidemiology of hypertension -- sect. 2. Pathophysiology. Pathophysiology of hypertension -- Blood pressure genetics -- The sympathetic nervous system in acute and chronic blood pressure elevation -- Environmental and psychosocial stress in hypertension onset and progression -- Renin -- Angiotensin-converting enzymes: properties and function -- Angiotensin-(1-7) -- The angiotensin receptors: AT b1 s and AT b2 s -- Aldosterone and mineralocorticoids -- The role of insulin resistance and compensatory hyperinsulinemia in patients with essential hypertension -- Remodeling of resistance arteries in hypertension -- Clinical applications of arterial stiffness in hypertension -- Endothelium in hypertension: nitric oxide --Endothelin in hypertension -- Natriuretic peptides -- Vasodilator peptides: CGRP, substance P, and adrenomedullin -- The Kallikrein-Kinin System as a regulator of cardiovascular and renal function -- Sect. 3. Target organ damage/cardiovascular events. The concept of total risk -- New interpretations of blood pressure: the importance of pulse pressure -- Coronary atherosclerotic sequelae of hypertension -- Left ventricular hypertrophy, congestive heart failure, and coronary flow reserve abnormalities in hypertension -- Renal protection in chronic kidney disease -- sect. 4. Diagnosis. Initial evaluation and follow-up assessment -- Prognostic and diagnostic value of ambulatory blood pressure monitoring -- White-coat hypertension -- Sect. 5. Treatment: general considerations. The blood pressure lowering treatment trialists' collaboration (BPLTTC) -- The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT) -- The LIFE study -- The VALUE trial -- Main results from VALUE -- Clinical outcome trials of hypertension with angiotensin receptor blockers -- ACE inhibitor trials: effects in hypertension -- Critical assessment of hypertension guidelines -- Current prescribing practices -- Calcium channel blockers: controversies, lessons, and outcomes -- Nursing clinics in the management of hypertension -- Community outreach -- Medication adherence for antihypertensive therapy -- Sect. 6. Diet and nutrition. Diet: micronutrients -- Dietary approaches to hypertension management: the DASH studies -- Obesity and hypertension: impact on the cardiovascular and renal systems -- Alcohol and hypertension -- Obesity in hypertension: the role of diet and drugs -- Exercise and hypertension -- Sect. 7. Pharmacologic treatment. Initial choices in the treatment of hypertension -- Pharmacokinetics of antihypertensive drugs -- Fixed combination antihypertensive therapy -- Chronotherapeutics in the treatment of hypertension -- Sect. 8. Comorbid conditions and special populations in hypertension. Diabetes mellitus and the cardiovascular metabolic syndrome: reducing cardiovascular and renal events -- Hypertension in patients on renal replacement therapy -- Ischemic heart disease in hypertension -- Hypertension in the elderly -- Management of hypertension in Black populations -- Hypertension in pregnancy -- Hypertension in children -- Resistant hypertension -- Orthostatic hypotension and autonomic dysfunction syndromes -- Sect. 9. Individual drug classes. How antihypertensive drugs get approved in the United States -- Diuretics: mechanisms of action -- [beta]-adrenergic blockers -- [alpha]-adrenoceptor blockers -- Angiotensin-converting enzyme inhibitors -- Calcium antagonists -- Angiotensin II receptor antagonists -- Direct-acting smooth muscle vasodilators and adrenergic inhibitors -- Endothelin antagonists -- Mineralocorticoid receptor antagonists -- Vasopeptidase inhibitors -- Renin inhibitors -- Sect. 10. Secondary hypertension. Obstructive sleep apnea and hypertension -- Renovascular hypertension: diagnosis and treatment -- Adrenal cortex hypertension -- Phoechromocytoa: detection and management -- Anesthesia and hypertension -- Management of hypertensive emergencies and urgencies -- Aggressive blood pressure targets; developing effective algorithms.

The revised and updated 2nd Edition provides a logical, practical framework for managing patients with hypertension. Today's leading experts discuss all aspects of the field b7 sfrom pathophysiology, pharmacological treatments, and lifestyle modifications to secondary hypertension and cardiovascular complications. Assesses the risks of specific pharmacological treatments * offers expert analysis of recent clinical trials * and providesDelivers strategies for managing patients with comorbid conditions such as diabetes, renal disease, and ischemic heart disease.Explains the role of vascular biology in the pathogenesis of hypertension.

Electronic reproduction.
Amsterdam :
Elsevier Science & Technology,
2009.

Mode of access: World Wide Web.

ISBN: 9780721602585

Source: 30863:30865Elsevier Science & Technologyhttp://www.sciencedirect.comSubjects--Topical Terms:

825110
Hypertension.
Index Terms--Genre/Form:

542853
Electronic books.

LC Class. No.: RC685.H8 / H76783 2005

Dewey Class. No.: 616.1/32

National Library of Medicine Call No.: 2005 E-845

Hypertension = a companion to Brenner and Rector's the kidney /
LDR:06728cmm 2200385Ia 4500 001 1033504
003 OCoLC
005 20110615082805.0
006 m d
007 cr cn|||||||||
008 120420s2005 paua ob 001 0 eng d
020 $a 9780721602585
020 $a 0721602584
035 $a (OCoLC)489077447
035 $a ocn489077447
037 $a 30863:30865 $b Elsevier Science & Technology $n http://www.sciencedirect.com
040 $a OPELS $b eng $c OPELS $d DMJ
049 $a TEFA
050 1 4 $a RC685.H8 $b H76783 2005
060 1 4 $a 2005 E-845
060 1 4 $a WG 340 $b H99426 2005
082 0 4 $a 616.1/32 $2 22
245 0 0 $a Hypertension $h [electronic resource] : $b a companion to Brenner and Rector's the kidney / $c [edited by] Suzanne Oparil, Michael A. Weber.{me_controlnum}
246 3 $a Hypertension : $b a companion to Brenner and Rector's the kidney (Online)
250 $a 2nd ed.
260 $a Philadelphia : $b Elsevier Mosby, $c c2005.
300 $a xxv, 872 p. : $b ill. ; $c 29 cm.
500 $a Companion v. to Brenner & Rector's the kidney / edited by Barry M. Brenner. 7th ed. c2004.
504 $a Includes bibliographical references and index.
505 0 $a Sect. 1. Background and history. A history of hypertension treatment -- The National High Blood Pressure Education Program -- Epidemiology of hypertension -- sect. 2. Pathophysiology. Pathophysiology of hypertension -- Blood pressure genetics -- The sympathetic nervous system in acute and chronic blood pressure elevation -- Environmental and psychosocial stress in hypertension onset and progression -- Renin -- Angiotensin-converting enzymes: properties and function -- Angiotensin-(1-7) -- The angiotensin receptors: AT b1 s and AT b2 s -- Aldosterone and mineralocorticoids -- The role of insulin resistance and compensatory hyperinsulinemia in patients with essential hypertension -- Remodeling of resistance arteries in hypertension -- Clinical applications of arterial stiffness in hypertension -- Endothelium in hypertension: nitric oxide --Endothelin in hypertension -- Natriuretic peptides -- Vasodilator peptides: CGRP, substance P, and adrenomedullin -- The Kallikrein-Kinin System as a regulator of cardiovascular and renal function -- Sect. 3. Target organ damage/cardiovascular events. The concept of total risk -- New interpretations of blood pressure: the importance of pulse pressure -- Coronary atherosclerotic sequelae of hypertension -- Left ventricular hypertrophy, congestive heart failure, and coronary flow reserve abnormalities in hypertension -- Renal protection in chronic kidney disease -- sect. 4. Diagnosis. Initial evaluation and follow-up assessment -- Prognostic and diagnostic value of ambulatory blood pressure monitoring -- White-coat hypertension -- Sect. 5. Treatment: general considerations. The blood pressure lowering treatment trialists' collaboration (BPLTTC) -- The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT) -- The LIFE study -- The VALUE trial -- Main results from VALUE -- Clinical outcome trials of hypertension with angiotensin receptor blockers -- ACE inhibitor trials: effects in hypertension -- Critical assessment of hypertension guidelines -- Current prescribing practices -- Calcium channel blockers: controversies, lessons, and outcomes -- Nursing clinics in the management of hypertension -- Community outreach -- Medication adherence for antihypertensive therapy -- Sect. 6. Diet and nutrition. Diet: micronutrients -- Dietary approaches to hypertension management: the DASH studies -- Obesity and hypertension: impact on the cardiovascular and renal systems -- Alcohol and hypertension -- Obesity in hypertension: the role of diet and drugs -- Exercise and hypertension -- Sect. 7. Pharmacologic treatment. Initial choices in the treatment of hypertension -- Pharmacokinetics of antihypertensive drugs -- Fixed combination antihypertensive therapy -- Chronotherapeutics in the treatment of hypertension -- Sect. 8. Comorbid conditions and special populations in hypertension. Diabetes mellitus and the cardiovascular metabolic syndrome: reducing cardiovascular and renal events -- Hypertension in patients on renal replacement therapy -- Ischemic heart disease in hypertension -- Hypertension in the elderly -- Management of hypertension in Black populations -- Hypertension in pregnancy -- Hypertension in children -- Resistant hypertension -- Orthostatic hypotension and autonomic dysfunction syndromes -- Sect. 9. Individual drug classes. How antihypertensive drugs get approved in the United States -- Diuretics: mechanisms of action -- [beta]-adrenergic blockers -- [alpha]-adrenoceptor blockers -- Angiotensin-converting enzyme inhibitors -- Calcium antagonists -- Angiotensin II receptor antagonists -- Direct-acting smooth muscle vasodilators and adrenergic inhibitors -- Endothelin antagonists -- Mineralocorticoid receptor antagonists -- Vasopeptidase inhibitors -- Renin inhibitors -- Sect. 10. Secondary hypertension. Obstructive sleep apnea and hypertension -- Renovascular hypertension: diagnosis and treatment -- Adrenal cortex hypertension -- Phoechromocytoa: detection and management -- Anesthesia and hypertension -- Management of hypertensive emergencies and urgencies -- Aggressive blood pressure targets; developing effective algorithms.
520 $a The revised and updated 2nd Edition provides a logical, practical framework for managing patients with hypertension. Today's leading experts discuss all aspects of the field b7 sfrom pathophysiology, pharmacological treatments, and lifestyle modifications to secondary hypertension and cardiovascular complications. Assesses the risks of specific pharmacological treatments * offers expert analysis of recent clinical trials * and providesDelivers strategies for managing patients with comorbid conditions such as diabetes, renal disease, and ischemic heart disease.Explains the role of vascular biology in the pathogenesis of hypertension.
533 $a Electronic reproduction. $b Amsterdam : $c Elsevier Science & Technology, $d 2009. $n Mode of access: World Wide Web. $n System requirements: Web browser. $n Title from title screen (viewed on Dec. 9, 2009). $n Access may be restricted to users at subscribing institutions.
533 $a Electronic reproduction. $b St. Louis, MO. : $c MD Consult, LLC., $d [2009?]. $n Online version of print publication $n Mode of access: World Wide Web. $n Access may be restricted to users at subscribing institutions.
650 0 $a Hypertension. $3 825110
650 1 2 $a Hypertension $x therapy. $3 860826
650 2 2 $a Antihypertensive Agents $x therapeutic use. $3 708814
650 2 2 $a Hypertension $x complications. $3 863878
650 2 2 $a Hypertension $x physiopathology. $3 661219
650 2 2 $a Life Style. $3 650433
650 1 7 $a Hypertensie. $2 gtt $3 1363953
650 7 $a Hipertens�ao (farmacologia;tratamento) $2 larpcal $3 1363954
650 7 $a Cardiopatias. $2 larpcal $3 1363955
655 7 $a Electronic books. $2 lcsh $3 542853
700 1 $a Oparil, Suzanne. $3 1363950
700 1 $a Weber, Michael A., $d 1942- $3 1363951
700 1 $a Brenner, Barry M., $d 1937- $t Brenner & Rector's the kidney. $3 1363952
710 2 $a ScienceDirect (Online service) $3 848416
710 2 $a MD Consult LLC. $3 1363704
776 1 $c Original $z 0721602584 $z 9780721602585 $w (DLC) 2004051303 $w (OCoLC)56567478
856 4 0 $3 ScienceDirect $u http://www.sciencedirect.com/science/book/9780721602585 $z An electronic book accessible through the World Wide Web; click for information
994 $a C0 $b TEF